Showing results (311-320 of 527) with videos related to
Sort By:
Pageof 53
Journal of Experimental & Clinical Cancer Research : CR|October 29, 2023
CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB responseBelinda Palermo, Ornella Franzese, Giuseppe Frisullo, et al.Cancers|July 2, 2021
Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical FeaturesAntonio Passaro, Silvia Novello, Diana Giannarelli, et al.Oncology Reviews|March 30, 2026
How recreational therapies impact physiological and psychosocial outcomes in cancer patients: a reviewMarika D'Oria, Calogero Casà, Cristina Cenci, et al.Cancer|August 10, 2005
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trialsPaolo Carlini, Emilio Bria, Diana Giannarelli, et al.Critical Reviews in Oncology/Hematology|August 12, 2018
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancerIlaria Trestini, Luisa Carbognin, Sara Monteverdi, et al.Journal of Experimental & Clinical Cancer Research : CR|May 17, 2011
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trialsFederica Cuppone, Emilio Bria, Vanja Vaccaro, et al.Future Oncology (London, England)|December 20, 2014
BMI variation increases recurrence risk in women with early-stage breast cancerPalma Fedele, Laura Orlando, Paola Schiavone, et al.Clinical Lung Cancer|May 26, 2022
Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung CancerSalma K Jabbour, Byoung Chul Cho, Emilio Bria, et al.Cancers|March 14, 2020
c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR InhibitorsAntonia Strippoli, Alessandra Cocomazzi, Michele Basso, et al.Tumori|June 30, 2026
Beyond the calendar: A narrative review on chronobiological drivers of prognosis in resectable NSCLCGiovanni Leuzzi, Pamela Minicozzi, Paolo Verderio, et al.Pageof 53